Clinical follow-up
The results of the 12-month follow-up are presented in Table 3 and
Figure 1. In the DAPT group, OAC with VKA and NOAC was restarted in 14
(6.4%) patients. Reasons were ischemic stroke (n=5), pulmonary
embolism/deep vein thrombosis (n=5), thrombus on the ventricular
electrode of an indwelling implantable cardioverter-defibrillator (n=1),
significant peri-device flow (n=2), and DRT (n=1). DAPT was prolonged to
12 months in nine (4.1%) patients due to concomitant coronary heart
disease. In the ACT group, 17 (5.6%) patients resumed oral
anticoagulation with VKA or NOACs. Reasons were ischemic stroke (n=8),
pulmonary embolism/deep vein thrombosis (n=6) and DRT (n=3). Ten (3.3%)
were still on DAPT for coronary heart disease.